Ülke: Birleşik Krallık
Dil: İngilizce
Kaynak: MHRA (Medicines & Healthcare Products Regulatory Agency)
Gliclazide
Advanz Pharma
A10BB09
Gliclazide
30mg
Modified-release tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 06010201; GTIN: 5021691032724 5021691032731
OBJECT 1 Vamju 30 mg modified-release tablets Summary of Product Characteristics Updated 01-Jul-2021 | ADVANZ Pharma • 1. Name of the medicinal product • 2. Qualitative and quantitative composition • 3. Pharmaceutical form • 4. Clinical particulars • 4.1 Therapeutic indications • 4.2 Posology and method of administration • 4.3 Contraindications • 4.4 Special warnings and precautions for use • 4.5 Interaction with other medicinal products and other forms of interaction • 4.6 Fertility, pregnancy and lactation • 4.7 Effects on ability to drive and use machines • 4.8 Undesirable effects • 4.9 Overdose • 5. Pharmacological properties • 5.1 Pharmacodynamic properties • 5.2 Pharmacokinetic properties • 5.3 Preclinical safety data • 6. Pharmaceutical particulars • 6.1 List of excipients • 6.2 Incompatibilities • 6.3 Shelf life • 6.4 Special precautions for storage • 6.5 Nature and contents of container • 6.6 Special precautions for disposal and other handling • 7. Marketing authorisation holder • 8. Marketing authorisation number(s) • 9. Date of first authorisation/renewal of the authorisation • 10. Date of revision of the text 1. Name of the medicinal product Vamju 30 mg modified-release tablets 2. Qualitative and quantitative composition Vamju 30 mg: Each modified-release tablet contains 30 mg gliclazide. Excipients with known effect: Lactose Vamju 30 mg: Each 30 mg tablet contains 81.9 mg lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. Pharmaceutical form Modified-release tablet. Vamju 30 mg White, biconvex, capsule-shaped tablet, engraved with “GLI 30” on one side and plain on the other side, with dimensions 10.0 x 4.5 mm. 4. Clinical particulars 4.1 Therapeutic indications Vamju is indicated in adults for treatment of non-insulin dependent diabetes (type 2) when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose. 4.2 Posology and method of administration Posology The daily do Belgenin tamamını okuyun